Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to its initial public offering [1][2]. Group 1: Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. - The company's lead product candidate, azelaprag, is designed to enhance weight loss as an orally available small-molecule agonist of the apelin receptor [3]. Group 2: Legal Allegations - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, concerning investors who purchased stock during BioAge's IPO on September 26, 2024 [2]. - The complaint alleges that BioAge misrepresented the safety and efficacy of its STRIDES Phase 2 trial for azelaprag, which was conducted in collaboration with Eli Lilly and Company [4]. Group 3: Trial and Stock Impact - BioAge's STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - Following the announcement of the trial's discontinuation on December 6, 2024, BioAge's stock price plummeted over 76%, from 4.65 per share within three days [6].
BIOA SECURITIES LAWSUIT: BioAge Investors that Lost Money may have been affected by Misconduct -- Contact BFA Law by March 10 Class Action Deadline (NASDAQ:BIOA)